Talis One COVID-19 Test
Detection of SARS-CoV-2 infection
Approved (EUA)Discontinued
Key Facts
Indication
Detection of SARS-CoV-2 infection
Phase
Approved (EUA)
Status
Discontinued
Company
About Talis Biomedical
Talis Biomedical was established to revolutionize diagnostic testing with its integrated, cartridge-based Talis One platform, designed to deliver lab-quality molecular results at the point of care in approximately 30 minutes. The company went public in 2021 but subsequently encountered commercial and operational hurdles, including manufacturing scale-up issues and lower-than-expected demand for its COVID-19 test. Following a strategic review, Talis has ceased commercial operations, reduced its workforce, and is actively seeking potential mergers, acquisitions, or other strategic transactions.
View full company profile